Literature DB >> 15178332

Direct fluorometric measurement of hepatitis C virus helicase activity.

Anna M Boguszewska-Chachulska1, Mariusz Krawczyk, Anna Stankiewicz, Agnieszka Gozdek, Anne-Lise Haenni, Ludmila Strokovskaya.   

Abstract

The non-structural protein 3 (NS3) of hepatitis C virus (HCV) is a highly promising target for anti-HCV therapy because of its multiple enzymatic activities, such as RNA-stimulated nucleoside triphosphatase, RNA helicase and serine protease. The helicase domain of NS3 as well as domain 2 of the helicase were expressed in a baculovirus system to obtain in high yield active proteins for prospective studies of complexes of the helicase with its inhibitors. A novel direct fluorometric test of helicase activity with a quenched DNA substrate, 3' labeled with a Cy3 dye and 5' labeled with a Black Hole Quencher, was developed and optimal reaction conditions established. This test based on fluorescence resonance energy transfer is simple and fast. It allows for direct measurements of enzyme activity, circumventing laborious and complicated radioactive techniques that are poorly reproducible. The results obtained encourage us to propose this new fluorescent assay as a method enabling high throughput screening of anti-helicase compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178332     DOI: 10.1016/j.febslet.2004.04.072

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

1.  Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.

Authors:  Eloise Mastrangelo; Margherita Pezzullo; Tine De Burghgraeve; Suzanne Kaptein; Boris Pastorino; Kai Dallmeier; Xavier de Lamballerie; Johan Neyts; Alicia M Hanson; David N Frick; Martino Bolognesi; Mario Milani
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

2.  Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase.

Authors:  Alicia M Hanson; John J Hernandez; William R Shadrick; David N Frick
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 3.  Fluorescent DNA-based enzyme sensors.

Authors:  Nan Dai; Eric T Kool
Journal:  Chem Soc Rev       Date:  2011-02-02       Impact factor: 54.564

4.  Role of divalent metal cations in ATP hydrolysis catalyzed by the hepatitis C virus NS3 helicase: magnesium provides a bridge for ATP to fuel unwinding.

Authors:  David N Frick; Sukalyani Banik; Ryan S Rypma
Journal:  J Mol Biol       Date:  2006-11-07       Impact factor: 5.469

5.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

6.  Monitoring helicase activity with molecular beacons.

Authors:  Craig A Belon; David N Frick
Journal:  Biotechniques       Date:  2008-10       Impact factor: 1.993

7.  NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system.

Authors:  Agnieszka Gozdek; Igor Zhukov; Agnieszka Polkowska; Jaroslaw Poznanski; Anna Stankiewicz-Drogon; Jerzy M Pawlowicz; Wlodzimierz Zagórski-Ostoja; Peter Borowski; Anna M Boguszewska-Chachulska
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

8.  DndEi Exhibits Helicase Activity Essential for DNA Phosphorothioate Modification and ATPase Activity Strongly Stimulated by DNA Substrate with a GAAC/GTTC Motif.

Authors:  Tao Zheng; Pan Jiang; Bo Cao; Qiuxiang Cheng; Lingxin Kong; Xiaoqing Zheng; Qinghai Hu; Delin You
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.157

9.  Fuel specificity of the hepatitis C virus NS3 helicase.

Authors:  Craig A Belon; David N Frick
Journal:  J Mol Biol       Date:  2009-03-28       Impact factor: 5.469

10.  Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.

Authors:  Kohji Moriishi; Yashiharu Matsuura
Journal:  Front Microbiol       Date:  2012-02-14       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.